Program
mavacamten
Also written as “Mavacamten” and “MYK-461”.
Its studies are mostly in Cardiomyopathy, Hypertrophic · Anthrax, led by 2 companies.
Drug pageMYK-461: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 194 open or running | phase 4since Oct 27, 2023 | Dec 19, 2014 | Dec 13, 2027phase 4 · NCT07004972 |
| LianBioits history only | 20 open or running | phase 3since Dec 13, 2021 | Oct 28, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 7 earlier studies, Dec 19, 2014 to Apr 5, 2018.
- Dec 9, 2016Named mavacamtenINNProposed as its International Nonproprietary Name in WHO's List 116 · before, MYK-461
- Oct 24, 2018Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT03723655 · 314 enrolled · United States, Belgium, Czechia and more
- Apr 7, 2020Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT04349072 · 112 enrolled · United States
- Feb 16, 2021Phase 2 study in Cardiomyopathy, Familial Restrictive, 3Bristol-Myers Squibb · NCT04766892 · 30 enrolled · United States, Canada
- Oct 28, 2021LianBio’s first study: phase 1 study in Cardiomyopathy, HypertrophicNew to LianBioLianBio · NCT05135871 · 45 enrolled · China
- Dec 13, 2021Phase 3 study in Cardiomyopathy, HypertrophicLianBio · NCT05174416 · 81 enrolled · China
- Apr 1, 2022Phase 1 study in AnthraxBristol-Myers Squibb · NCT05320094 · 45 enrolled · United States
- May 2, 2022Phase 1 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05362045 · 158 enrolled · United States
- Jun 7, 2022Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05414175 · 38 enrolled · Japan
- Sep 14, 2022Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05582395 · 580 enrolled · United States, Australia, Austria and more
- Jan 31, 2023Phase 1 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05719805 · 84 enrolled · United States
- Oct 27, 2023Phase 4 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT06112743 · 63 enrolled · United States, Argentina, Australia and more
- Feb 2, 2024Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT06253221 · 44 enrolled · United States, Australia, Canada and more
- May 26, 2025Phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · NCT07004972 · 50 enrolled · India
- Oct 29, 2026Phase 3 study in CardiomyopathiesBristol-Myers Squibb · NCT07940777 · 500 planned
Ahead
- Dec 13, 2027Primary completion: phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · NCT07004972
- Jul 21, 2029Primary completion: phase 3 study in CardiomyopathiesBristol-Myers Squibb · NCT07940777
TargetBeta
“Cardiac myosin inhibitor”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| omecamtiv mecarbilrule | Cytokinetics | phase 3 | 16 |
| danicamtivrule | Bristol-Myers Squibb | phase 3 | 7 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07940777Cardiomyopathies | 3 | Not yet recruiting | Bristol-Myers Squibb | Jul 21, 2029 | 500 |
| NCT07004972Symptomatic Obstructive Hypertrophic Cardiomyopathy · India | 4 | Active, not recruiting | Bristol-Myers Squibb | Dec 13, 2027 | 50 |
| NCT06253221Cardiomyopathy, Hypertrophic · United States, Australia, Canada and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Nov 25, 2025 | 44 |
| NCT06112743Cardiomyopathy, Hypertrophic · United States, Argentina, Australia and more | 4 | Active, not recruiting | Bristol-Myers Squibb | Jul 16, 2026 | 63 |
| NCT05719805Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Bristol-Myers Squibb | Jul 25, 2023 | 84 |
| NCT05582395Cardiomyopathy, Hypertrophic · United States, Australia, Austria and more | 3 | Terminated | Bristol-Myers Squibb | Mar 6, 2025 | 580 |
| NCT05414175Cardiomyopathy, Hypertrophic · Japan | 3 | Completed | Bristol-Myers Squibb | Nov 27, 2023 | 38 |
| NCT05362045Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Bristol-Myers Squibb | Aug 19, 2022 | 158 |
| NCT05320094Anthrax · United States | 1 | Completed | Bristol-Myers Squibb | Sep 11, 2022 | 45 |
| NCT05174416Cardiomyopathy, Hypertrophic · China | 3 | Completed | LianBio | Mar 6, 2023 | 81 |
| NCT05135871Cardiomyopathy, Hypertrophic · China | 1 | Completed | LianBio | Feb 5, 2022 | 45 |
| NCT04766892Cardiomyopathy, Familial Restrictive, 3 · United States, Canada | 2 | Completed | Bristol-Myers Squibb | Feb 26, 2024 | 30 |
| NCT04349072Cardiomyopathy, Hypertrophic · United States | 3 | Completed | Bristol-Myers Squibb | Feb 7, 2022 | 112 |
| NCT03723655Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more | 3 | Completed | Bristol-Myers Squibb | Jan 16, 2026 | 314 |
| NCT03496168Cardiomyopathy, Hypertrophic · United States | 2 | Completed | Bristol-Myers Squibb | Nov 9, 2023 | 13 |
| NCT03470545Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more | 3 | Completed | Bristol-Myers Squibb | Mar 14, 2020 | 251 |
| NCT03442764Non-obstructive Hypertrophic Cardiomyopathy · United States | 2 | Completed | Bristol-Myers Squibb | Jan 7, 2020 | 59 |
| NCT02842242Cardiomyopathy, Hypertrophic · United States | 2 | Completed | Bristol-Myers Squibb | Nov 2017 | 21 |
| NCT02480296Healthy · Australia | 1 | Completed | Bristol-Myers Squibb | Jul 2016 | 60 |
| NCT02356289Cardiomyopathy, Hypertrophic · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Jul 2015 | 48 |
| NCT02329184Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Bristol-Myers Squibb | Mar 2016 | 15 |
How it is read
Names in the registry
- “Mavacamten”, 12 entries
- “mavacamten”, 5 entries
- “MYK-461”, 4 entries
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 18 studies
- Anthrax, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.